{"id":35571,"date":"2021-01-11T14:57:30","date_gmt":"2021-01-11T14:57:30","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=35571"},"modified":"2023-05-10T15:17:13","modified_gmt":"2023-05-10T14:17:13","slug":"katharina-billian-frey","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/","title":{"rendered":"Katharina Billian-Frey"},"content":{"rendered":"<div class=\"vgblk-rw-wrapper limit-wrapper\">\n\n\t<h2>Dr. Katharina Billian-Frey<\/h2>\n<h4>Head of Protein Engineering at Apogenix AG<\/h4>\n\t<p>Dr. Katharina Billian-Frey has strong expertise in antibody-based immuno-oncology drugs and protein engineering. She joined the Drug Discovery Unit of Apogenix in 2018, first as senior scientist and is currently heading the Protein Engineering Group. Her main focus at Apogenix lies in the development of biotherapeutic agonistic drugs targeting the TNFR receptor superfamily.<\/p>\n<p>Prior to Apogenix, she worked at HI-STEM, a spin-off company of the German Cancer Research Center. She was responsible for the development of an antibody drug discovery pipeline for cancer stem cell derived targets, including recombinant antigen expression and phage display-based selection of drug candidate antibodies.<\/p>\n<p>Katharina Billian-Frey received her PhD from the ETH Zurich on antibody-based immunocytokines for targeting the tumor vasculature. She holds a diploma in Technical Biology from the University of Stuttgart with a focus on antibody fusion proteins.<\/p>\n\t\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/01\/Katharina_Billian-Frey_Apogenix_BioTech_Pharma_Summit_2020_Gallery.jpg\" alt=\"Katharina_Billian-Frey_Apogenix_BioTech_Pharma_Summit_2020_Gallery\" itemprop=\"image\" height=\"1224\" width=\"820\" title=\"Katharina_Billian-Frey_Apogenix_BioTech_Pharma_Summit_2020_Gallery\" onerror=\"this.style.display='none'\"  sizes=\"auto, (max-width: 768px) 100vw, 100vw\" srcset=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/01\/Katharina_Billian-Frey_Apogenix_BioTech_Pharma_Summit_2020_Gallery.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/01\/Katharina_Billian-Frey_Apogenix_BioTech_Pharma_Summit_2020_Gallery-201x300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/01\/Katharina_Billian-Frey_Apogenix_BioTech_Pharma_Summit_2020_Gallery-686x1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/01\/Katharina_Billian-Frey_Apogenix_BioTech_Pharma_Summit_2020_Gallery-768x1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/01\/Katharina_Billian-Frey_Apogenix_BioTech_Pharma_Summit_2020_Gallery-630x940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/01\/Katharina_Billian-Frey_Apogenix_BioTech_Pharma_Summit_2020_Gallery-420x627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/01\/Katharina_Billian-Frey_Apogenix_BioTech_Pharma_Summit_2020_Gallery-315x470.jpg 315w\" \/>\t\t\t\t\t\t\t\n<h3>\n\tSingle-chain TNFSF ligands as building blocks for costimulatory bispecifics\n\t<\/h3>\n\t<ul>\n<li>Engineering of trivalent single-chain TNFSF ligands generates building blocks for bispecific fusion proteins with a 3+1 agonist-to-target binding mode for improved biological activity<\/li>\n<li>Immune-costimulatory properties of scCD40L and sc4-1BBL can be combined with any antibody of interest<\/li>\n<li>Combination of scCD40L or sc4-1BBL with aPD-L1 demonstrates target-dependent agonistic activation of immune cells<\/li>\n<\/ul>\n\t<a href=\"https:\/\/sociopharma.com\/\" target=\"_blank\" role=\"button\" rel=\"noopener\">\n\t\t\t\t\tPresentation available only at SocioPharma.com\n\t<\/a>\n<h4>\n\t\t\t<a href=\"#\" title=\"On the Web\" target=\"_self\" rel=\"noopener\">\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/apogenix.com\/en\/\" target=\"_blank\" rel=\"noopener\">https:\/\/apogenix.com\/<\/a><\/p>\n<h4>\n\t\t\t<a href=\"#\" title=\"On LinkedIn\" target=\"_self\" rel=\"noopener\">\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.linkedin.com\/in\/katharina-billian-frey-a8864829\/\" target=\"_blank\" rel=\"noopener\">Visit Profile<\/a><\/p>\n\n<\/div><!-- .vgblk-rw-wrapper -->","protected":false},"excerpt":{"rendered":"<p>Dr. Katharina Billian-Frey Head of Protein Engineering at Apogenix AG Dr. Katharina Billian-Frey has strong expertise in antibody-based immuno-oncology drugs and protein engineering. She joined the Drug Discovery Unit of Apogenix in 2018, first as senior scientist and is currently heading the Protein Engineering Group. Her main focus at Apogenix lies in the development of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":35572,"parent":34722,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-35571","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Katharina Billian-Frey &#8226; BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"Dr. Katharina Billian-Frey has strong expertise in antibody-based immuno-oncology drugs and protein engineering. She joined the Drug Discovery Unit of Apogenix in 2018\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Katharina Billian-Frey &#8226; BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"Dr. Katharina Billian-Frey has strong expertise in antibody-based immuno-oncology drugs and protein engineering. She joined the Drug Discovery Unit of Apogenix in 2018\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-10T14:17:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/01\/Katharina_Billian-Frey_Apogenix_BioTech_Pharma_Summit_2020_Profile.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/\",\"name\":\"Katharina Billian-Frey &#8226; BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/01\/Katharina_Billian-Frey_Apogenix_BioTech_Pharma_Summit_2020_Profile.jpg\",\"datePublished\":\"2021-01-11T14:57:30+00:00\",\"dateModified\":\"2023-05-10T14:17:13+00:00\",\"description\":\"Dr. Katharina Billian-Frey has strong expertise in antibody-based immuno-oncology drugs and protein engineering. She joined the Drug Discovery Unit of Apogenix in 2018\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/01\/Katharina_Billian-Frey_Apogenix_BioTech_Pharma_Summit_2020_Profile.jpg\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/01\/Katharina_Billian-Frey_Apogenix_BioTech_Pharma_Summit_2020_Profile.jpg\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antibody Engineering &#038; Therapeutics 2021 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Katharina Billian-Frey\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow&#039;s healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Katharina Billian-Frey &#8226; BioTech Pharma Summit","description":"Dr. Katharina Billian-Frey has strong expertise in antibody-based immuno-oncology drugs and protein engineering. She joined the Drug Discovery Unit of Apogenix in 2018","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/","og_locale":"en_US","og_type":"article","og_title":"Katharina Billian-Frey &#8226; BioTech Pharma Summit","og_description":"Dr. Katharina Billian-Frey has strong expertise in antibody-based immuno-oncology drugs and protein engineering. She joined the Drug Discovery Unit of Apogenix in 2018","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2023-05-10T14:17:13+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/01\/Katharina_Billian-Frey_Apogenix_BioTech_Pharma_Summit_2020_Profile.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/","name":"Katharina Billian-Frey &#8226; BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/01\/Katharina_Billian-Frey_Apogenix_BioTech_Pharma_Summit_2020_Profile.jpg","datePublished":"2021-01-11T14:57:30+00:00","dateModified":"2023-05-10T14:17:13+00:00","description":"Dr. Katharina Billian-Frey has strong expertise in antibody-based immuno-oncology drugs and protein engineering. She joined the Drug Discovery Unit of Apogenix in 2018","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/01\/Katharina_Billian-Frey_Apogenix_BioTech_Pharma_Summit_2020_Profile.jpg","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/01\/Katharina_Billian-Frey_Apogenix_BioTech_Pharma_Summit_2020_Profile.jpg","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/katharina-billian-frey\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Antibody Engineering &#038; Therapeutics 2021 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/"},{"@type":"ListItem","position":3,"name":"Katharina Billian-Frey"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow&#039;s healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/35571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=35571"}],"version-history":[{"count":6,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/35571\/revisions"}],"predecessor-version":[{"id":38354,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/35571\/revisions\/38354"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/34722"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/35572"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=35571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}